BRITISH COLUMBIA | Ministry of Health

PHARMACARE SPECIAL AUTHORITY REQUEST

TARGETED DMARDs FOR PSORIATIC ARTHRITIS

INITIAL / SWITCH

HLTH 5360 Rev. 2025/03/13

◯ **INITIAL**
Complete sections 1 – 3, 5

◯ **SWITCH**
Complete sections 1 – 4, 5A – 5C

For up-to-date criteria and forms, please check: www.gov.bc.ca/pharmacarespecialauthority

Fax requests to 1-800-609-4884 (toll free) OR mail requests to: PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4
This facsimile is Doctor privileged and contains confidential information intended only for PharmaCare. Any other distribution, copying or disclosure is strictly prohibited.

If PharmaCare approves this Special Authority request, approval is granted solely for the purpose of covering prescription costs. PharmaCare approval does not indicate that the requested medication is, or is not, suitable for any specific patient or condition.

If you have received this fax in error, please write MISDIRECTED across the front of the form and fax toll-free to 1-800-609-4884, then destroy the pages received in error.

Forms with information missing will be returned for completion. If no prescriber fax or mailing address is provided, PharmaCare will be unable to return a response.

SECTION 1 – RHEUMATOLOGIST INFORMATION

Prescriber's Name and Mailing Address	
College ID (use ONLY College ID number)	Phone Number (include area code)
CRITICAL FOR A TIMELY RESPONSE →	Prescriber's Fax Number

SECTION 2 – PATIENT INFORMATION

Patient (Family) Name	
Patient (Given) Name(s)	
Date of Birth (YYYY / MM / DD)	Date of Application (YYYY / MM / DD)
CRITICAL FOR PROCESSING →	Personal Health Number (PHN)

SECTION 3 – CURRENT CLINICAL INFORMATION

MEDICATION REQUESTED

◯ **ADALIMUMAB:** Abrilada®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma®
40 mg every two weeks

◯ **CERTOLIZUMAB** 400 mg at 0, 2, and 4 weeks, followed by 200 mg every other week or 400 mg every 4 weeks

◯ **ETANERCEPT:** Brenzys®, Erelzi®, Rymti®
50 mg weekly

◯ **GOLIMUMAB** 50 mg SC once per month

◯ **INFLIXIMAB IV:** Avsola®, Ixifi®, Remdantry™, Renflexis®
3-5 mg/kg at 0, 2, and 6 weeks then every 8 weeks thereafter

◯ **IXEKIZUMAB** 160 mg at week 0, then 80 mg every 4 weeks thereafter

◯ **SECUKINUMAB**
◯ 150 MG ◯ 300 MG
At weeks 0, 1, 2, 3, and 4 followed by monthly maintenance dosing. 300 mg dosing considered if prior anti-TNF failure with ongoing active psoriatic arthritis, or if patient has coexistent moderate to severe plaque psoriasis

◯ **USTEKINUMAB** Jamteki™, Steqeyma®, Wezlana™
45 mg SC at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90 mg SC may be used in patients with a body weight >100 kg

YEAR OF DIAGNOSIS OF PSORIATIC ARTHRITIS	WEIGHT (KG)	ESR or CRP	MORNING STIFFNESS (MINUTES)	PHYSICIAN GLOBAL ASSESSMENT of ***INFLAMMATION*** (scale of 0-10, 0=None, 10=severe active disease)

CURRENT MEDICATIONS (DMARDs, anti-inflammatories, corticosteroids, analgesics, opioids)

DRUG	DOSE	FREQUENCY

PHARMACARE USE ONLY

Please complete additional information on page 2 >>

STATUS	EFFECTIVE DATE	DURATION OF THERAPY / TERMINATION DATE

PATIENT NAME	PHN	DATE (YYYY / MM / DD)

SECTION 4 – MOST RECENT TARGETED DMARD AND REASON FOR DISCONTINUATION

Additional information regarding prior targeted DMARD trial(s) will be requested if required.

NAME, DOSE & FREQUENCY	APPROX. DURATION OF USE	FAILURE		SIDE EFFECT(S) OR OTHER DETAILS - SPECIFY
		TYPE I*	TYPE II**	
		◯	◯	

* Never achieving a 20% improvement ** At least 20% improvement in first 12 weeks of a TNF inhibitor (24 weeks for abatacept and rituximab) but loss of benefit

SECTION 5 - CRITERIA FOR COVERAGE OF ONE YEAR – Patient must meet criteria in A, B, C and D below

A Current Status Of Cutaneous Psoriasis: ◯ none ◯ mild ◯ moderate ◯ severe

B ☐ Diagnosis of moderate to severe psoriatic arthritis, where patient currently exhibits at least **two** of the following (please indicate all that apply):

- ☐ Five or more active joints **(if yes, complete homunculus below)**.
- ☐ If oligoarticular (less than five joints), at least one active joint proximal to, or including, wrist or ankle **(if yes, complete homunculus below)**.
- ☐ More than one joint with erosion on imaging study.
- ☐ Dactylitis of two or more digits **(indicate by arrow and "D" on homunculus below)**.
- ☐ Tenosynovitis refractory to oral NSAIDs AND steroid injections **(indicate by arrow and "TS" on homunculus below)**.
- ☐ Enthesitis refractory to oral NSAIDs AND steroid injections (not required for Achilles tendon) **(indicate by arrow and "E" on homunculus below)**.
- ☐ Inflammatory spinal symptoms refractory to two NSAIDs (minimum 2 week trial each) and submit a BASDAI with a score greater than 4.
- ☐ Daily use of corticosteroids to control active arthritis.
- ☐ Use of narcotics >12 hours per day for pain resulting from inflammation.

Specify drug and daily dose _____

C ☐ Functional assessment completed by patient and attached.

☐ Health Assessment Questionnaire (HAQ) **AND/OR** ☐ BASDAI (in spinal disease)

D ☐ Patient has failed two or more DMARDs:

	DOSE	FREQUENCY	DURATION	RESPONSE/ADVERSE EVENT
☐ Sulfasalazine (if allergic, must have failed **two** of the medications listed below).				
☐ Methotrexate: up to 25 mg (15 mg if over 65 years) parenteral weekly				
☐ Chloroquine and/or hydroxychloroquine				
☐ Leflunomide				
☐ Cyclosporine				
☐ Other (eg azathioprine, gold - specify below):				

HOMUNCULUS

Indicate active joints, dactylitis, tenosynovitis and enthesitis



Report all adverse events to the post-market surveillance program, Canadian Vigilance, toll-free 1-866-234-2345 (health professionals only).

Personal information on this form is collected under the authority of, and in accordance with, the *British Columbia Pharmaceutical Services Act* 22(1) and *Freedom of Information and Protection of Privacy Act* 26 (a),(c),(e). The information is being collected for the purposes of (a) administering the PharmaCare program, (b) analyzing, planning and evaluating the Special Authority and other Ministry programs and (c) to manage and plan for the health system generally. If you have any questions about the collection of this information, call Health Insurance BC from Vancouver at 1-604-683-7151 or from elsewhere in BC toll free at 1-800-663-7100 and ask to consult a pharmacist concerning the Special Authority process.

I have discussed with the patient that the purpose of releasing their information to PharmaCare is to obtain Special Authority for prescription coverage and for the purposes set out here.

_____

Rheumatologist's Signature (Mandatory)

PharmaCare may request additional documentation to support this Special Authority request. Actual reimbursement is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement, and to any other applicable PharmaCare pricing policy.

TARGETED DMARDs FOR PSORIATIC ARTHRITIS

Save Print Clear Form